ReviewCureus2023
The Role of Serological Markers in the Prediction of Disease Course and Response to Therapy in Inflammatory Bowel Disease.
Review in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 5 citations in OpenAlex.
- Plasma proteomic markers predict risk for bowel resection in inflammatory bowel disease: a retrospective cohort study.International journal of surgery (London, England) · 2026Article
- Association of serological markers with endoscopic mucosal healing and disease activity in patients with inflammatory bowel disease: a retrospective study.Frontiers in immunology · 2026Article
- From blood to bowel: correlating serological markers with mucosal healing and inflammation in patients with inflammatory bowel disease.Frontiers in immunology · 2026Article
- Irritable Bowel Syndrome in Inflammatory Bowel Disease: An Evidence-Based Practical Review.Journal of clinical medicine · 2025Review
- Cross-Disciplinary Mechanistic Insights in Molecular Medicine.Current issues in molecular biology · 2025Article
- Performance Evaluation of Open Channel Buhlmann Fecal Calprotectin Turbo Assay on Abbott Alinity C Analyzer.Diagnostics (Basel, Switzerland) · 2024Article
- Changes in the Expression of Genes Regulating the Response to Hypoxia, Inflammation, Cell Cycle, Apoptosis, and Epithelial Barrier Functioning during Colitis-Associated Colorectal Cancer Depend on Individual Hypoxia Tolerance.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a common gastrointestinal tract disease and can be divided into two major groups: ulcerative colitis (UC) and Crohn's disease (CD). These two entities can be diagnosed from a combination of invasive and non-invasive tests as well as a thorough history and physical examination. However, invasive tests are preferred for a definitive diagnosis since the two entities have characteristic features of colonoscopy and biopsy. In this review, the following will be discussed: how non-invasive tests could help detect the presence of IBD, how markers help monitor disease progression, and how the disease responds to treatment. Some of the common markers that are discussed in detail include perinuclear antineutrophil cytoplasmatic antibodies (p-ANCA), anti-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.